Skip to content
Screener

McKesson MCK Oncology & Multispecialty — Total revenues

Other segment segments

North American Pharmaceutical
$86.77B—
Medical-Surgical Solutions
$2.82B+4.4%
Prescription Technology Solutions
$1.57B+9.2%

Similar metrics at other companies

Gilead Sciences logo
GILDTotal Oncology — Total revenues
$873M+2.8%
Schrodinger logo
SDGROncology, Neurology, and Immunology Product — Total revenues
$500K-28.6%
Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$102.7B+16.8%
Enterprise value$110.42B+14.5%
P/E22.4×-5.4×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%—
Debt / equity2×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: McKesson’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:29 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000927653-26-000234
(In millions)Three Months Ended June 30, 2026Three Months Ended June 30, 2025
Segment revenues (1)
North American Pharmaceutical$86,773$82,729
Oncology & Multispecialty14,22210,658
Prescription Technology Solutions1,5661,434
Medical-Surgical Solutions2,8192,701
Other—305
Total revenues$105,380$97,827
Other segment expense, net (2)

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is McKesson's oncology & multispecialty — total revenues?
McKesson (MCK) reported oncology & multispecialty — total revenues of $14.22B in Q2 2026.
How has McKesson's oncology & multispecialty — total revenues changed year-over-year?
McKesson's oncology & multispecialty — total revenues increased by 33.4% year-over-year, from $10.66B to $14.22B.
What is the long-term trend for McKesson's oncology & multispecialty — total revenues?
Over 2 years (2024 to 2026), McKesson's oncology & multispecialty — total revenues has grown at a 26.0% compound annual growth rate (CAGR), from $30.49B to $48.42B.
What does oncology & multispecialty — total revenues mean?
This metric represents the total gross revenue generated by the Oncology and Multispecialty segment from the sale of pharmaceutical products and related services. It is a primary indicator of the segment's market demand, pricing power, and overall scale within the healthcare supply chain.

Ask your AI about McKesson's oncology & multispecialty — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude